Mutation Clearance after Transplantation for Myelodysplastic Syndrome.

doi:10.1056/NEJMoa1804714

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Mutation Clearance after Transplantation for Myelodysplastic Syndrome.

The New England journal of medicine - 13 Sept 2018

Duncavage Eric J, Jacoby Meagan A, Chang Gue Su, Miller Christopher A, Edwin Natasha, Shao Jin, Elliott Kevin, Robinson Joshua, Abel Haley, Fulton Robert S, Fronick Catrina C, O'Laughlin Michelle, Heath Sharon E, Brendel Kimberly, Saba Raya, Wartman Lukas D, Christopher Matthew J, Pusic Iskra, Welch John S, Uy Geoffrey L, Link Daniel C, DiPersio John F, Westervelt Peter, Ley Timothy J, Trinkaus Kathryn, Graubert Timothy A, Walter Matthew J

Abstract excerpt

BACKGROUND: Allogeneic hematopoietic stem-cell transplantation is the only curative treatment for patients with myelodysplastic syndrome (MDS). The molecular predictors of disease progression after transplantation are unclear. METHODS: We sequenced bone marrow and skin samples from 90 adults with MDS who underwent allogeneic hematopoietic stem-cell transplantation after a myeloablative or reduced-intensity...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bone Marrow Examination

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease-Free Survival

Share to Hematopoietic Stem Cell Transplantation

Share to Myelodysplastic Syndromes

Share to Skin

Share to Survival Analysis

Share to Transplantation Conditioning

Share to Transplantation, Homologous

Source

Open in PubMed Open full text

Identifiers

PMID: 30207916
DOI: 10.1056/NEJMoa1804714
PMCID: PMC6309244

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mutation Clearance after Transplantation for Myelodysplastic Syndrome.PMID 30207916Read ↗

Impact of spliceosome mutation on outcomes of myelodysplastic syndrome and chronic myelomonocytic leukemia patients undergoing allogeneic hematopoietic cell transplantation.Semantic proximity Read ↗

Clinical Effects of Driver Somatic Mutations on the Outcomes of Patients With Myelodysplastic Syndromes Treated With Allogeneic Hematopoietic Stem-Cell TransplantationSemantic proximity Read ↗

Knowledge to date on secondary malignancy following hematopoietic cell transplantation for sickle cell diseaseSemantic proximity Read ↗

Subclones dominate at MDS progression following allogeneic hematopoietic cell transplant.Semantic proximity Read ↗

Patient-Specific Measurable Residual Disease Markers Predict Outcome in Patients With Myelodysplastic Syndrome and Related Diseases After Hematopoietic Stem-Cell TransplantationSemantic proximity Read ↗

The Prognostic Value of Early Detection of Minimal Residual Disease as Defined by Flow Cytometry and Gene Mutation Clearance for Myelodysplastic Syndrome Patients After Myeloablative Allogeneic Hematopoietic Stem-Cell TransplantationSemantic proximity Read ↗

Remission Status Prior to Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia/Myelodysplastic Syndrome Patients Harboring Single-Hit or Multi-Hit p53 Mutations Does Not Impact Outcome.Semantic proximity Read ↗

Postallogeneic monitoring with molecular markers detected by pretransplant next-generation or Sanger sequencing predicts clinical relapse in patients with myelodysplastic/myeloproliferative neoplasms.Semantic proximity Read ↗

Allogeneic Hematopoietic Stem Cell Transplantation Is Underutilized in Older Patients with Myelodysplastic SyndromesSemantic proximity Read ↗

Simultaneous Monitoring of Mutation and Chimerism Using Next-Generation Sequencing in Myelodysplastic SyndromeSemantic proximity Read ↗

Early post-transplant molecular residual disease predicts outcomes in myelodysplastic neoplasms and myelodysplastic neoplasms/acute myeloid leukemia undergoing allogeneic transplantationSemantic proximity Read ↗

IMPACT OF CONDITIONING INTENSITY AND GENOMICS ON RELAPSE AFTER ALLOGENEIC TRANSPLANTATION FOR PATIENTS WITH MYELODYSPLASTIC SYNDROMESemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.